Treatment with Plk1-targeting siRNNs in two pediatric B-ALL cell lines, SupB15 and 697, induced a ~60% statistically significant (p < 0.001) knockdown of Plk1 mRNA (Fig. 1A,B). This evidence concerns the gene PLK1 and acute lymphoblastic leukemia.